Last reviewed · How we verify
HRS-2189 Tablets
At a glance
| Generic name | HRS-2189 Tablets |
|---|---|
| Sponsor | Shandong Suncadia Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer (PHASE1, PHASE2)
- Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HRS-2189 Tablets CI brief — competitive landscape report
- HRS-2189 Tablets updates RSS · CI watch RSS
- Shandong Suncadia Medicine Co., Ltd. portfolio CI